Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 1832853, 10 pages
https://doi.org/10.1155/2017/1832853
Research Article

Anti-Inflammatory Effect of Dialyzable Leukocyte Extract in Autoimmune Prostatitis: Evaluation in Animal Model

1ENMH, Instituto Politécnico Nacional, Ciudad de México, Mexico
2CBG, Instituto Politécnico Nacional, Cd. Reynosa, TAMPS, Mexico
3Hospital General Milpa Alta, Ciudad de México, Mexico
4Hospital de Traumatología, IMSS, Ciudad de México, Mexico
5Farmainmune, Ciudad de México, Mexico

Correspondence should be addressed to D. Guillermo Pérez Ishiwara; xm.moc.oohay@xmarawihsi

Received 3 November 2016; Revised 13 January 2017; Accepted 14 February 2017; Published 12 March 2017

Academic Editor: Humberto H. Lara

Copyright © 2017 Carlos Pérez-Alvarado et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Bajpayee, K. Kumar, S. Sharma et al., “Prostatitis: prevalence, health impact and quality improvement strategies,” Acta Poloniae Pharmaceutica—Drug Research, vol. 69, no. 4, pp. 571–579, 2012. View at Google Scholar · View at Scopus
  2. Y. H. Sung, J. H. Jung, S. H. Ryang, S. J. Kim, and K. J. Kim, “Clinical significance of national institutes of health classification in patients with chronic prostatitis/chronic pelvic pain syndrome,” Korean Journal of Urology, vol. 55, no. 4, pp. 276–280, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Ludwig, C. Steltz, P. Huwe, R. Schäffer, M. Altmannsberger, and W. Weidner, “Immunocytological analysis of leukocyte subpopulations in urine specimens before and after prostatic massage,” European Urology, vol. 39, no. 3, pp. 277–282, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Maccioni, V. E. Rivero, and C. M. Riera, “Prostatein (or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis,” Clinical and Experimental Immunology, vol. 112, no. 2, pp. 159–165, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. R. D. Motrich, M. Maccioni, A. A. Ponce, G. A. Gatti, J. P. Mackern Oberti, and V. E. Rivero, “Pathogenic consequences in semen quality of an autoimmune response against the prostate gland: from animal models to human disease,” Journal of Immunology, vol. 177, no. 2, pp. 957–967, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Z. Altuntas, F. Daneshgari, E. Veizi et al., “A novel murine model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by immunization with a spermine binding protein (p25) peptide,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 304, no. 6, pp. R415–R422, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Penna, S. Amuchastegui, C. Cossetti et al., “Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol,” Journal of Immunology, vol. 177, no. 12, pp. 8504–8511, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Acosta, N. Pérez, E. Pérez et al., “Anti-inflammatory effect of dialysable leucocyte extract in a rat model of osteoarthritis: histopathological and molecular characterization,” Scandinavian Journal of Rheumatology, pp. 1–8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Stanciková, J. Rovenský, J. Pekárek, E. Orviský, S. Blazícková, and K. Cech, “Influence of various forms of dialyzable leukocyte extracts on rat adjuvant arthritis,” Archivum Immunologiae et Therapiae Experimentalis, vol. 42, no. 4, pp. 295–299, 1994. View at Google Scholar · View at Scopus
  10. M. Armides Franco-Molina, E. Mendoza-Gamboa, P. Castillo-Tello et al., “In vitro antibacterial activity of bovine dialyzable leukocyte extract,” Immunopharmacology and Immunotoxicology, vol. 28, no. 3, pp. 471–483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. H. Lara, L. Ixtepan-Turrent, E. N. Garza-Trevĩo, J. I. Badillo-Almaraz, and C. Rodriguez-Padilla, “Antiviral mode of action of bovine dialyzable leukocyte extract against human immunodeficiency virus type 1 infection,” BMC Research Notes, vol. 4, article 474, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Pizza, C. De Vinci, D. Cuzzocrea et al., “A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer,” Biotherapy, vol. 9, no. 1–3, pp. 123–132, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Galmarini, M. E. Ferro, and C. M. Riera, “Delayed hypersensitivity and lesions following isoimmunization with modified rat male accessory glands: kinetics of induction,” Journal of Reproductive Immunology, vol. 13, no. 2, pp. 147–157, 1988. View at Publisher · View at Google Scholar · View at Scopus
  14. P. T. Adegun, O. M. Ogundele, D. T. Falode et al., “Mapping angiogenic cells CD31 (PECAM1) and CD45 in PCa and BPH biopsies,” Journal of Cancer Research and Experimental Oncology, vol. 5, no. 1, pp. 1–7, 2013. View at Google Scholar
  15. M. R. U. Galheigo, A. R. Cruz, Á. S. Cabral et al., “Role of the TNF-α receptor type 1 on prostate carcinogenesis in knockout mice,” Prostate, vol. 76, no. 10, pp. 917–926, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Sugihara, O. Maeda, M. Tsuji et al., “Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: An Immunohistochemical Study,” Oncology Reports, vol. 5, no. 6, pp. 1389–1394, 1998. View at Google Scholar · View at Scopus
  17. M. Royuela, M. P. De Miguel, A. Ruiz et al., “Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression,” European Cytokine Network, vol. 11, no. 1, pp. 119–127, 2000. View at Google Scholar · View at Scopus
  18. Y. Du, Q. Long, L. Zhang et al., “Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling,” International Journal of Oncology, vol. 47, no. 6, pp. 2064–2072, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Miličević, M. Mrčela, J. Galić, and K. Marjanović, “Expression of proinflammatory cytokine interleukin-6 in tissue samples of human prostate obtained by needle biopsy,” Pathology Research and Practice, vol. 211, no. 11, pp. 865–870, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. You, Y. Dong, X. Kong, Y. Zhang, R. L. Vessella, and J. Melamed, “Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers,” Neoplasia, vol. 9, no. 6, pp. 464–470, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. T. A. Moseley, D. R. Haudenschild, L. Rose, and A. H. Reddi, “Interleukin-17 family and IL-17 receptors,” Cytokine and Growth Factor Reviews, vol. 14, no. 2, pp. 155–174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. S. F. Murphy, A. J. Schaeffer, J. Done et al., “IL17 mediates pelvic pain in experimental autoimmune prostatitis (EAP),” PLoS ONE, vol. 10, no. 5, Article ID e0125623, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Debinski, R. K. Puri, R. J. Kreitman, and I. Pastan, “A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin,” Journal of Biological Chemistry, vol. 268, no. 19, pp. 14065–14070, 1993. View at Google Scholar · View at Scopus
  24. R. Goldstein, C. Hanley, J. Morris et al., “Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer,” Cancers, vol. 3, no. 4, pp. 4281–4293, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. H. H. Lara, L. I. Turrent, E. N. Garza-Treviño, R. Tamez-Guerra, and C. Rodriguez-Padilla, “Clinical and immunological assessment in breast cancer patients receiving anticancer therapy and bovine dialyzable leukocyte extract as an adjuvant,” Experimental and Therapeutic Medicine, vol. 1, no. 3, pp. 425–431, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Medina-Rivero, G. Merchand-Reyes, L. Pavón et al., “Batch-to-batch reproducibility of Transferon™,” Journal of Pharmaceutical and Biomedical Analysis, vol. 88, pp. 289–294, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. M. E. Hernandez, D. Mendieta, M. Pérez-Tapia et al., “Effect of selective serotonin reuptake inhibitors and immunomodulator on cytokines levels: an alternative therapy for patients with major depressive disorder,” Clinical and Developmental Immunology, vol. 2013, Article ID 267871, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. A. Franco-Molina, E. Mendoza-Gamboa, P. Zapata-Benavides et al., “IMMUNEPOTENT CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I study in non-small cell lung cancer patients,” Cytotherapy, vol. 10, no. 5, pp. 490–496, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Mendoza-Gamboa, M. A. Franco-Molina, P. Zapata-Benavides et al., “Bovine dialyzable leukocyte extract modulates AP-1 DNA-binding activity and nuclear transcription factor expression in MCF-7 breast cancer cells,” Cytotherapy, vol. 10, no. 2, pp. 212–219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. E. V. Vykhovanets, S. Shukla, G. T. MacLennan, O. V. Vykhovanets, D. R. Bodner, and S. Gupta, “Il-1β-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation,” Prostate, vol. 69, no. 6, pp. 633–643, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. A. J. Duclos, C.-T. Lee, and D. A. Shoskes, “Current treatment options in the management of chronic prostatitis,” Therapeutics and Clinical Risk Management, vol. 3, no. 4, pp. 507–512, 2007. View at Google Scholar · View at Scopus
  32. D. L. Ribeiro, A. Rafacho, J. R. Bosqueiro, S. R. Taboga, and R. M. Góes, “Cellular changes in the prostatic stroma of glucocorticoid-treated rats,” Cell and Tissue Research, vol. 332, no. 3, pp. 499–508, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. C.-C. Peng, J.-H. Liu, C.-H. Chang et al., “Action mechanism of Ginkgo biloba leaf extract intervened by exercise therapy in treatment of benign prostate hyperplasia,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 408734, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. C. M. Pérez-Alvarado, C. Gómez García, M. Reyes López et al., “Chronic prostatitis/chronic pelvic pain syndrome: histological evidences of treatment with an immunotherapeutic agent in a murine model,” Journal of Chemical, Biological and Physical Sciences, vol. 4, no. 5, pp. 26–32, 2014. View at Google Scholar
  35. G. Pace, C. Di Massimo, D. De Amicis, C. Vicentini, and M. Giuliana Tozzi Ciancarelli, “Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer,” International Braz J Urol, vol. 37, no. 5, pp. 617–622, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. V. E. Rivero, P. Iribarren, and C. M. Riera, “Mast cells in accessory glands of experimentally induced prostatitis in male Wistar rats,” Clinical Immunology and Immunopathology, vol. 74, no. 3, pp. 236–242, 1995. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Papadoukakis, A. Kyroudi-Voulgari, M. C. Truss, D. Perea, and D. Mitropoulos, “Quantitative study of mast cells in experimentally induced benign prostatic hyperplasia,” Urologia Internationalis, vol. 84, no. 1, pp. 100–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Penna, S. Amuchastegui, C. Cossetti et al., “Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse,” Journal of Immunology, vol. 179, no. 3, pp. 1559–1567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Rivero, C. Carnaud, and C. M. Riera, “Prostatein or steroid binding protein (PSBP) induces experimental autoimmune prostatitis (EAP) in NOD mice,” Clinical Immunology, vol. 105, no. 2, pp. 176–184, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. B. W. Simons, N. M. Durham, T. C. Bruno et al., “A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression,” Journal of Pathology, vol. 235, no. 3, pp. 478–489, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. B. I. Yoon, W. J. Bae, S. J. Kim et al., “The anti-inflammatory effects of a new herbal formula (WSY-1075) in a nonbacterial prostatitis rat model,” The World Journal of Men's Health, vol. 31, no. 2, pp. 150–156, 2013. View at Publisher · View at Google Scholar
  42. K. C. Chen, S. Y. Sung, Y. T. Lin et al., “Benign prostatic hyperplasia complicated with T1DM can be alleviated by treadmill exercise-evidences revealed by the rat model,” BMC Urology, vol. 15, article 113, 2015. View at Google Scholar
  43. S. Bernichtein, N. Pigat, P. Camparo et al., “Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia,” Prostate, vol. 75, no. 7, pp. 706–722, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Kramer, G. E. Steiner, A. Handisurya et al., “Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation,” Prostate, vol. 52, no. 1, pp. 43–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. K. A. Lang Kuhs, A. Hildesheim, B. Trabert et al., “Association between regular aspirin use and circulating markers of inflammation: a study within the prostate, lung, colorectal, and ovarian cancer screening trial,” Cancer Epidemiology Biomarkers and Prevention, vol. 24, no. 5, pp. 825–832, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. E. V. Vykhovanets, S. Shukla, G. T. MacLennan et al., “Molecular imaging of NF-kappaB in prostate tissue after systemic administration of IL-1β,” Prostate, vol. 68, no. 1, pp. 34–41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Wu, Y. Guo, F. Jia, and X. Wang, “The effects of armillarisin A on serum IL-1β and IL-4 and in treating ulcerative colitis,” Cell Biochemistry and Biophysics, vol. 72, no. 1, pp. 103–106, 2015. View at Publisher · View at Google Scholar · View at Scopus